Company Overview

PlasmaTech, Inc. (OTC: PMAH) is a publicly traded company that has historically been associated with the biotechnology and specialty pharmaceutical sector, with a particular focus on plasma-derived therapeutics and healthcare-related acquisitions. Public disclosures and historical market records indicate that the company previously operated under variations of the PlasmaTech name and pursued strategies centered on acquiring or developing healthcare and biopharmaceutical assets. Available information from historical filings, OTC market disclosures, and financial databases suggests the company’s activities were tied to specialty biologics, plasma-based therapies, and related intellectual property initiatives.

The company’s historical business model appears to have relied primarily on acquisitions, licensing arrangements, and the development or commercialization of healthcare-related products rather than large-scale manufacturing operations. Publicly available records indicate that the company underwent multiple strategic and corporate restructurings over time. However, current operational details, active revenue-generating business lines, and updated financial disclosures are limited. Data inconclusive based on available public sources regarding the company’s present operating scale, commercial activity, and long-term strategic positioning.

Business Operations

Historical disclosures indicate that PlasmaTech, Inc. pursued operations through healthcare-oriented subsidiaries and acquisition targets connected to biotechnology and plasma-related therapeutics. The company previously referenced interests in specialty pharmaceutical development, therapeutic technologies, and healthcare commercialization activities. Public information suggests that operations were concentrated primarily within the United States, with limited evidence of substantial international operating infrastructure.

Available records do not clearly identify active large-scale operating segments, manufacturing facilities, or diversified business units comparable to larger publicly traded biotechnology firms. Historical announcements referenced partnerships and acquisition activity involving healthcare and pharmaceutical entities, but the operational status and financial contribution of many of these initiatives remain unclear in recent public reporting. Data inconclusive based on available public sources regarding current subsidiaries, active joint ventures, and recurring revenue streams.

Strategic Position & Investments

Historically, the company’s strategy centered on acquiring healthcare-related assets and positioning itself within niche areas of biotechnology and specialty therapeutics. Public disclosures and historical investor materials referenced interests in plasma-derived products, pharmaceutical intellectual property, and emerging healthcare technologies. The company also pursued restructuring initiatives and corporate transactions intended to expand its healthcare portfolio and market visibility.

There is limited recent verified information regarding active growth investments, significant acquisitions, or ongoing research and development programs. Publicly available filings and OTC disclosures do not provide sufficient current detail to confirm the status of prior strategic initiatives or portfolio companies. Data inconclusive based on available public sources regarding active investment programs, material acquisitions, or emerging technology exposure as of the most recent reporting periods.

Geographic Footprint

Historical records indicate that PlasmaTech, Inc. was headquartered in the United States and primarily focused on domestic operations. Public filings and OTC disclosures do not show evidence of a broad multinational operational footprint or significant direct international revenue exposure. The company’s historical activities appear to have been concentrated in U.S.-based healthcare and biotechnology markets.

There is no clearly verifiable evidence from recent public disclosures indicating substantial operating presence across Europe, Asia-Pacific, Latin America, or other major international regions. While certain healthcare or licensing activities may have involved international counterparties, the extent of overseas operations or investment influence cannot be conclusively verified from available public records.

Leadership & Governance

Public information regarding current leadership and governance is limited and, in some cases, inconsistent across market databases and historical filings. Historical management teams associated with the company included executives involved in biotechnology commercialization, corporate restructuring, and healthcare acquisitions. However, up-to-date executive and board information is not consistently available through recent public filings.

Historical leadership references associated with the company include:

• Steven D. Lavin – Former executive leadership role associated with historical corporate operations
• Carl M. Green – Former executive leadership role referenced in historical company materials

Recent verified information regarding the current Chief Executive Officer, executive management team, or board composition is limited. Data inconclusive based on available public sources regarding current leadership structure, governance policies, and long-term management strategy.